Live Evaluations
The Many Shades of Plaque Psoriasis: Considerations for Treating Skin of Color
About
The Many Shades of Plaque Psoriasis: Considerations for Treating Skin of Color
This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.
Learning Objectives
At the completion of this activity, participants should be better able to:
Highlight the key different clinical presentations of plaque psoriasis in skin of color (SOC)
Review the unique treatment goals in patients with SOC that have psoriasis
Classify the role of novel targeted agents for the management of plaque psoriasis in SOC
Intended Audience
Faculty
Andrew Alexis, MD, MPH
Vice-Chair for Diversity and Inclusion, Dept. of Dermatology
Professor of Clinical Dermatology
Weill Cornell Medicine
New York, NY
Mona Shahriari, MD
Dermatologist
Central CT Dermatology
Cromwell, CT
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: BMS, LEO, Novartis, Almirall
Consultant: Leo, Galderma, Pfizer, Sanofi- Regeneron
Speakers’ Bureau or Honoraria: Regeneron, SANOFI-Genzyme, Pfizer, BMS
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.